The efficacy and safety of multiple-dose intravenous tranexamic acid in reducing perioperative blood loss in patients with thoracolumbar burst fracture

Clin Neurol Neurosurg. 2020 Jun:193:105766. doi: 10.1016/j.clineuro.2020.105766. Epub 2020 Mar 2.

Abstract

Objective: To evaluate the efficacy and safety of tranexamic acid (TXA) for single-segment thoracolumbar burst fracture without neurologic injury underwent pedicle screw fixation via Wiltse approach.

Patients and methods: We identified 264 patients with single-segment thoracolumbar burst fracture without neurologic injury underwent pedicle screw fixation via Wiltse approach (January 2016-June 2019) at a single center. The cohort was separated into three groups. Group A received 20 mg/kg TXA at 5 min before skin incision and 16 h after first dose; Group B received 20 mg/kg TXA at 5 min before skin incision; Group C received NS at each same time point. The outcomes were evaluated by hidden blood loss (HBL), total blood loss (TBL), intraoperative blood loss (IBL), transfusion rate, maximum hemoglobin (Hb) drop, prethrombotic state molecular markers, liver and renal function, coagulation function, inflammatory factor and adverse events.

Results: The HBL, TBL and maximum Hb drop were significantly lower in Group A than those of Group B and Group C, while the difference between Group B and Group C was statistically significant. The IBL was significantly lower in Group A and Group B than that of Group C. However, there was no significantly difference among the three groups in live and renal function, coagulation function, prethrombotic state molecular markers, transfusion rate and complications during the perioperative period. There was significantly lower level of interleukin-6 (IL-6) in Group A than Group C at the day after surgery, and lower level of C-reactive protein (CRP) at the third day after surgery.

Conclusions: Intravenous TXA used in the treatment of thoracolumbar burst fracture underwent pedicle screw fixation via Wiltse approach is effective and safe in decreasing perioperative blood loss. The two-dose TXA regimen can further reduce blood loss and alleviate post-operative inflammation response, without affecting prethrombotic state molecular marks and without increasing the risk of complications.

Keywords: Inflammation response; Perioperative blood loss; Prethrombotic state molecular marks; Thoracolumbar burst fracture; Tranexamic acid; Wiltse approach.

MeSH terms

  • Administration, Intravenous
  • Adult
  • Antifibrinolytic Agents / adverse effects
  • Antifibrinolytic Agents / therapeutic use*
  • Blood Loss, Surgical / prevention & control*
  • Blood Transfusion
  • C-Reactive Protein / analysis
  • Cohort Studies
  • Female
  • Fracture Fixation, Internal / methods*
  • Hemoglobins / analysis
  • Humans
  • Interleukin-6 / blood
  • Lumbar Vertebrae / injuries
  • Lumbar Vertebrae / surgery
  • Male
  • Middle Aged
  • Neurosurgical Procedures / methods*
  • Pedicle Screws
  • Retrospective Studies
  • Spinal Fractures / surgery*
  • Thoracic Vertebrae / injuries
  • Thoracic Vertebrae / surgery
  • Tranexamic Acid / adverse effects
  • Tranexamic Acid / therapeutic use*

Substances

  • Antifibrinolytic Agents
  • Hemoglobins
  • IL6 protein, human
  • Interleukin-6
  • Tranexamic Acid
  • C-Reactive Protein